Colorectal liver metastases (CRLM), cancer that has spread from the colon or rectum to the liver, have a deadly reputation. Due to its pervasive spread, typical cancer treatments like chemotherapy and ...

The U.S. Food and Drug Administration (FDA) has granted traditional approval to Braftovi (encorafenib) for adult patients ...

The BRAFTOVI combination regimen is the only approved targeted regimen for first-line BRAF-V600E mutant metastatic colorectal cancerPivotal results from the Phase 3 portion with mFOLFOX6 of the ...

The FDA has approved the first combination, targeted regimen for previously untreated BRAF V600E mutation-positive metastatic colorectal cancer.Encorafenib (Braftovi, Pfizer) plus cetuximab (Erbitux, ...

Review highlights how transplant oncology is expanding liver transplantation for selected primary and metastatic liver cancers.

Delcath Systems, Inc.’s Q3 revenue was pressured by weak patient starts, but 2026 growth prospects remain strong. Click for how DCTH stock valuation looks low.

Breta Hasimi struggled to speak when she received the diagnosis of triple-negative breast cancer, one of the most aggressive ...

The FDA has granted full approval to Pfizer Inc.’s Braftovi when used with Eli Lilly’s Erbitux (cetuximab) and fluorouracil‑based chemotherapy for adults with metastatic colorectal cancer carrying a ...

The U.S.-based biotech specializes in treating cancers with small molecules, antibody-drug conjugates, and other ...

Currently, no consensus exists regarding the definition of oligometastatic pancreatic ductal adenocarcinoma, its necessary diagnostic measures, and potential treatment approaches. To address these ...

Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has granted full approval to BRAFTOVI® (encorafenib) in ...

A family say they have been ‘overwhelmed’ by the outpouring of support from strangers as they face one of the most difficult times of their lives ...